(European Society of Cardiology) The IL-1β inhibitor canakinumab lowers the risk of cardiovascular disease and lung cancer risk by reducing inflammation, according to late-breaking results from the CANTOS trial presented today in a Hot Line -- LBT Session at ESC Congress1 and published in the NEJM.
from EurekAlert! - Social and Behavioral Science http://ift.tt/2vDylc4
No comments:
Post a Comment